ZA201706059B - Method of treatment with tradipitant - Google Patents
Method of treatment with tradipitantInfo
- Publication number
- ZA201706059B ZA201706059B ZA2017/06059A ZA201706059A ZA201706059B ZA 201706059 B ZA201706059 B ZA 201706059B ZA 2017/06059 A ZA2017/06059 A ZA 2017/06059A ZA 201706059 A ZA201706059 A ZA 201706059A ZA 201706059 B ZA201706059 B ZA 201706059B
- Authority
- ZA
- South Africa
- Prior art keywords
- tradipitant
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
- Medicinal Preparation (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Eye Examination Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128472P | 2015-03-04 | 2015-03-04 | |
| US201562232644P | 2015-09-25 | 2015-09-25 | |
| PCT/US2016/021015 WO2016141341A1 (en) | 2015-03-04 | 2016-03-04 | Method of treatment with tradipitant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201706059B true ZA201706059B (en) | 2023-08-30 |
Family
ID=55629110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/06059A ZA201706059B (en) | 2015-03-04 | 2017-09-06 | Method of treatment with tradipitant |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US10463655B2 (enExample) |
| EP (2) | EP3730140B1 (enExample) |
| JP (4) | JP6891385B2 (enExample) |
| KR (3) | KR20170122777A (enExample) |
| CN (2) | CN107427502B (enExample) |
| AU (4) | AU2016226006B2 (enExample) |
| BR (1) | BR112017018620A2 (enExample) |
| CA (2) | CA2978736C (enExample) |
| CL (1) | CL2017002238A1 (enExample) |
| DK (1) | DK3265087T3 (enExample) |
| ES (1) | ES2824552T3 (enExample) |
| HR (1) | HRP20201627T1 (enExample) |
| HU (1) | HUE050944T2 (enExample) |
| IL (1) | IL254142B (enExample) |
| MX (2) | MX385788B (enExample) |
| PT (1) | PT3265087T (enExample) |
| RU (1) | RU2770050C2 (enExample) |
| WO (1) | WO2016141341A1 (enExample) |
| ZA (1) | ZA201706059B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3265087T (pt) * | 2015-03-04 | 2020-10-15 | Vanda Pharmaceuticals Inc | Método de tratamento com tradipitant |
| US11549147B2 (en) * | 2017-09-13 | 2023-01-10 | Vanda Pharmaceuticals Inc. | Treatment of atopic dermatitis with tradipitant |
| SI3710000T1 (sl) * | 2017-11-17 | 2025-07-31 | Vanda Pharmaceuticals Inc. | Tradipitant za uporabo pri zdravljenju gastropareze |
| CA3101210A1 (en) | 2018-06-08 | 2019-12-12 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| MX2020008456A (es) * | 2018-09-28 | 2020-09-25 | Vanda Pharmaceuticals Inc | Uso de tradipitant para tratar la cinetosis. |
| US20220096449A1 (en) * | 2018-12-03 | 2022-03-31 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2020132513A1 (en) | 2018-12-21 | 2020-06-25 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| EP4110335B1 (en) * | 2020-02-25 | 2025-10-15 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| WO2021195205A1 (en) | 2020-03-26 | 2021-09-30 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| AU2023413130A1 (en) | 2022-12-21 | 2025-06-05 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| US20250255855A1 (en) | 2024-02-09 | 2025-08-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9305718D0 (en) * | 1993-03-19 | 1993-05-05 | Glaxo Group Ltd | Medicaments |
| TW263498B (enExample) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| GB9513972D0 (en) | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
| DK1394150T3 (da) | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
| US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
| DK1501809T3 (da) | 2002-04-26 | 2008-05-13 | Lilly Co Eli | Trizolderivater som tachykininreceptorantagonister |
| JP4895476B2 (ja) * | 2002-04-26 | 2012-03-14 | イーライ リリー アンド カンパニー | タキキニン受容体アンタゴニスト |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7381826B2 (en) * | 2003-10-24 | 2008-06-03 | Eli Lilly And Company | Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| CA2643130A1 (en) | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compounds and methods of treating disorders associated with activation of metachromatic cells |
| SI2121610T1 (sl) * | 2006-12-20 | 2014-08-29 | Eli Lilly & Company | Nove vmesne spojine in postopek, ki je uporaben pri pripravi (2-(1-(3,5-bistrifluorometil-benzil)-5-piridin-4-il-1h-(1,2,3)triazol- 4-il)-piridin-3-il)-(2-klorofenil)-metanona |
| BR112012003263A2 (pt) | 2009-08-14 | 2015-09-22 | Opko Health Inc | formulações intravenosas de antagonistas de neuroquinina-1 |
| CN106512010A (zh) | 2009-11-18 | 2017-03-22 | 赫尔辛医疗股份公司 | 用于治疗中枢介导的恶心及呕吐的组合物及方法 |
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| EP2931253A1 (en) | 2012-12-13 | 2015-10-21 | Heron Therapeutics, Inc. | Pharmaceutical composition comprising antiemetic compounds and polyorthoester |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| KR20160023692A (ko) * | 2013-06-24 | 2016-03-03 | 타이거캣 파마, 인크. | 소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도 |
| US8906951B1 (en) * | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| PT3265087T (pt) * | 2015-03-04 | 2020-10-15 | Vanda Pharmaceuticals Inc | Método de tratamento com tradipitant |
| WO2016195723A1 (en) | 2015-06-03 | 2016-12-08 | Beller Pharmaceuticals LLC | Methods of treatment for conditions mediated by substance p |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| HUE053115T2 (hu) | 2015-11-30 | 2021-06-28 | Anacor Pharmaceuticals Inc | Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére |
| EA201891472A1 (ru) | 2015-12-22 | 2018-12-28 | Такеда Фармасьютикал Компани Лимитед | Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком |
| US11549147B2 (en) * | 2017-09-13 | 2023-01-10 | Vanda Pharmaceuticals Inc. | Treatment of atopic dermatitis with tradipitant |
| SI3710000T1 (sl) * | 2017-11-17 | 2025-07-31 | Vanda Pharmaceuticals Inc. | Tradipitant za uporabo pri zdravljenju gastropareze |
| CA3101210A1 (en) * | 2018-06-08 | 2019-12-12 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| MX2020008456A (es) * | 2018-09-28 | 2020-09-25 | Vanda Pharmaceuticals Inc | Uso de tradipitant para tratar la cinetosis. |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| US20220096449A1 (en) * | 2018-12-03 | 2022-03-31 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
-
2016
- 2016-03-04 PT PT167119312T patent/PT3265087T/pt unknown
- 2016-03-04 KR KR1020177026588A patent/KR20170122777A/ko not_active Ceased
- 2016-03-04 EP EP20180523.1A patent/EP3730140B1/en active Active
- 2016-03-04 HR HRP20201627TT patent/HRP20201627T1/hr unknown
- 2016-03-04 WO PCT/US2016/021015 patent/WO2016141341A1/en not_active Ceased
- 2016-03-04 RU RU2017134443A patent/RU2770050C2/ru active
- 2016-03-04 ES ES16711931T patent/ES2824552T3/es active Active
- 2016-03-04 CN CN201680013797.6A patent/CN107427502B/zh active Active
- 2016-03-04 CN CN202110527432.8A patent/CN113262221A/zh active Pending
- 2016-03-04 KR KR1020237043041A patent/KR102860817B1/ko active Active
- 2016-03-04 CA CA2978736A patent/CA2978736C/en active Active
- 2016-03-04 BR BR112017018620-9A patent/BR112017018620A2/pt not_active Application Discontinuation
- 2016-03-04 HU HUE16711931A patent/HUE050944T2/hu unknown
- 2016-03-04 JP JP2017546704A patent/JP6891385B2/ja active Active
- 2016-03-04 CA CA3213864A patent/CA3213864C/en active Active
- 2016-03-04 MX MX2017011279A patent/MX385788B/es unknown
- 2016-03-04 AU AU2016226006A patent/AU2016226006B2/en active Active
- 2016-03-04 US US15/553,394 patent/US10463655B2/en active Active
- 2016-03-04 DK DK16711931.2T patent/DK3265087T3/da active
- 2016-03-04 KR KR1020257030197A patent/KR20250136946A/ko active Pending
- 2016-03-04 EP EP16711931.2A patent/EP3265087B1/en active Active
-
2017
- 2017-08-24 IL IL254142A patent/IL254142B/en unknown
- 2017-09-04 MX MX2021010460A patent/MX2021010460A/es unknown
- 2017-09-04 CL CL2017002238A patent/CL2017002238A1/es unknown
- 2017-09-06 ZA ZA2017/06059A patent/ZA201706059B/en unknown
-
2019
- 2019-06-04 US US16/430,514 patent/US10772880B2/en active Active
- 2019-06-04 US US16/430,516 patent/US20190290626A1/en not_active Abandoned
-
2020
- 2020-07-31 US US16/944,596 patent/US11324735B2/en active Active
-
2021
- 2021-01-28 JP JP2021012356A patent/JP2021073258A/ja active Pending
- 2021-05-10 AU AU2021202956A patent/AU2021202956B2/en active Active
-
2022
- 2022-04-06 US US17/714,998 patent/US12318375B2/en active Active
-
2023
- 2023-01-18 JP JP2023006082A patent/JP2023052486A/ja active Pending
- 2023-09-21 AU AU2023233141A patent/AU2023233141B2/en active Active
-
2024
- 2024-04-09 JP JP2024062811A patent/JP2024074963A/ja not_active Withdrawn
-
2025
- 2025-03-12 US US19/078,214 patent/US20250205213A1/en active Pending
- 2025-08-04 AU AU2025210905A patent/AU2025210905A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279627A (en) | A method for treating depression | |
| GB201701673D0 (en) | Methods of well treatment | |
| IL254142A0 (en) | Method of treatment with Tardifitant | |
| PL3964213T3 (pl) | Leczenie zaburzeń zachowania | |
| GB201514760D0 (en) | Compounds and method of use | |
| GB201410116D0 (en) | Method of treatment | |
| ZA201705877B (en) | Method of treating diseases | |
| PL3220952T3 (pl) | Sposób leczenia lub zapobiegania udarowi | |
| GB201706406D0 (en) | Method of treatment | |
| EP3684342C0 (en) | TREATMENT PROCEDURES | |
| GB201815588D0 (en) | Method of treatment | |
| IL253028B (en) | treatment method | |
| IL253847A0 (en) | Methods of treating diseases | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201604627D0 (en) | Improved method of FT-IMS | |
| GB201506869D0 (en) | Method | |
| GB201602802D0 (en) | Method of treatment | |
| GB201513188D0 (en) | Method of tomography | |
| SG11201706885RA (en) | Novel treatment method | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201511017D0 (en) | Method of treatment | |
| GB201720439D0 (en) | Method of treatment | |
| GB201718589D0 (en) | Method of treatment | |
| GB201421982D0 (en) | Method of treatment |